Matica Invests in Quebec Topicals Research & Development Company

March 22, 2018 – Toronto, Ontario – Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) is pleased to announce that further to the Company news release dated February 8th, 2018 Matica has signed a definitive agreement (the “Agreement”) with Yunify Natural Technologies (“Yunify”), a Quebec based health and personal care research and innovation technology company. After the successful completion of due diligence and the signing of the definitive agreement, Matica has subscribed for a $2,000,000.00 convertible debenture bearing interest at six percent per annum.

Through the purchase of this convertible debenture, Matica will finance Yunify for $2,000,000.00.  The first tranche of $600,000.00 was paid on closing. A second tranche of $400,000.00 and the final tranche of $1,000,000 are due within the one year to maturity date. The debenture is convertible into units of Yunify at a $0.225 exercise price.  Each unit is comprised of one common share, one-half common share purchase warrant of which one full warrant will entitle the holder to purchase one common share of the Company for a period of 36 months from the closing date at an exercise price of $0.35 per warrant, and one-half common share purchase warrant of which one full warrant will entitle the holder to purchase one common share of the Company for a period of 36 months from the closing date at an exercise price of $0.50 per warrant. By fully exercising the warrants, Matica may acquire a 40 per cent interest in Yunify. 

Yunify is a Quebec based research and innovation company which creates personal care products and agricultural products. By teaming up with Yunify, Matica takes a leading role in new product development in the cannabis industry.  The Company recognizes the acute need for alternative cannabis delivery systems, especially through pain relief topicals. Matica will directly benefit from research and be able to produce new revolutionary topical products within the cannabis space. Yunify will create proprietary topical products for Matica based on its proprietary mineral and plant based suspension technologies. In addition to health and personal care products, Yunify is a leader in sustainable, clean, and green chemistries. Its technologies can be found in various market segments including: skincare, cosmetics, nutraceuticals and food growing agricultural products for open fields and green houses. The company is based in St-Hubert on the south shore of Montreal.

Yunify is a green biotechnology leader in cannabinoid-based active ingredient and delivery systems. Its unique hydro-mineral technology platform allows for the replacement of petroleum based and undesirable chemistries with truly sustainable green ingredients. The company focuses on three core business pillars: consumer personal care and nutraceuticals, agriculture and greenhouse growth inputs and functional innovations in related industries through discovery licensing.


For more information on Matica please visit the website at:


On behalf of the Board of Directors


/s/Boris Ziger

Boris Ziger, CEO & Chairman


The Company’s filings are available for review at and

For further information, please contact Boris Ziger, Chief Executive Officer, at:

Telephone: 416-304-9935




Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at

The CSE has not reviewed, approved or disapproved the content of this press release.